<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873234</url>
  </required_header>
  <id_info>
    <org_study_id>201507001-12</org_study_id>
    <nct_id>NCT02873234</nct_id>
  </id_info>
  <brief_title>A Study of Chinese Medicine Treating Depression</brief_title>
  <official_title>A Multicentre Prospective Cohort Study of Traditional Chinese Medicine Treating Depression With The Use of Cloud Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Third Affiliated Hospital of Beijing University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing HuiLongGuan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Henan University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Heilongjiang Chinese Medicine University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiamen Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wu Xi Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Third Affiliated Hospital of Beijing University of Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chinese Medicine syndrome differentiation has been a prevalent therapy in China for thousands
      of years. It is based on patients' symptoms, pulse, tongue and coating on the tongue.
      Therefore, the syndrome of patients and corresponding Traditional Chinese Medicine (TCM) may
      vary.

      This multicenter prospective cohort studies the efficiency and safety of TCM compared with
      antidepressants. A total number of 4600 cases with primary depression are expected to be
      collected and divided into 3 cohorts based on the patients' requirement and choices. Patients
      in one group will receive TCM, and patients in the other two groups will respectively receive
      antidepressants only and integrated treatment of TCM and antidepressants. This study has 2
      phases: treating period and the follow-up.

      The main purpose of this long-term study is to evaluate the efficiency of TCM compared with
      antidepressants in reducing relapse and suicide rate, changing lifestyle, improving patient
      compliance as well as the safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter prospective cohort uses a modern technique. With its help participants can
      assess themselves at any time and doctors can supervise patients in case of some adverse
      events or intervene when patients commit suicide.

      The main purpose of this study is to observe the differences between cohorts. However, the
      intra-group differences are also needed to be evaluated, as the therapies of different
      participants are various. Therefore, the number of participants treated with each therapy and
      the time of recovery need to be counted and analyzed. This is a long-term and natural study
      that participants lost, drug withdrawal and changes in participants'choices of the therapy
      cannot be avoided. So the reason and number of the previous conditions need to be observed.
      The safety of TCM and antidepressants is also a considerable outcome which will be evaluated
      by laboratory examination, Treatment Emergent Symptom Scale (TESS) and the number of
      participants with adverse events.

      Some of the outcomes are measured by questionnaires which can be divided into two parts. One
      is self-rated assessments including Self-rating Depression Scale (SDS) and Self-reporting
      Inventory (SCL-90). The other one is evaluated by doctors, such as Hamilton Depression Rating
      Scale of 24 items (HAMD), Montgomery-Asberg Depression Rating Scale (MADRS), Social
      Disability Screening Schedule (SDSS), Mini-mental State Examination (MMSE), Montreal
      Cognitive Assessment (MoCA)and Traditional Chinese Medicine syndrome score.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>2 years</time_frame>
    <description>It is the percentage of the relapse of depression including the total number of relapse cases.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicide rate</measure>
    <time_frame>2 years</time_frame>
    <description>The suicide rate includes the percentage of the cases committing suicide and the successful cases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-rating Depression Scale (SDS)</measure>
    <time_frame>2 years</time_frame>
    <description>Differences between groups are evaluated by the change of total scores from the study starting to every 2 weeks at least during 2 years. It is assessed by patients using a mobile phone APP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reporting Inventory (SCL-90)</measure>
    <time_frame>2 years</time_frame>
    <description>Differences between groups are evaluated by the change of total scores from the study starting to every 2 weeks at least during 2 years. It is assessed by patients using a mobile phone APP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale of 24 items (HAMD)</measure>
    <time_frame>before recruiting</time_frame>
    <description>Differences between groups are evaluated by change of total scores from the study intake to every 3 months in 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Disability Screening Schedule (SDSS)</measure>
    <time_frame>2 years</time_frame>
    <description>Differences between groups are evaluated by change of total scores from the study intake to every 3 months in 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Traditional Chinese Medicine syndrome score</measure>
    <time_frame>2 years</time_frame>
    <description>Before the study, all investigators took standardized training and conformance testing. Syndrome differentiation and syndrome scores were took by 2 investigators together, and the results needed to obtain their consent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery Rate</measure>
    <time_frame>2 years</time_frame>
    <description>The differences between groups are evaluated by the number and rate of recovery cases from the study intake to every 3 months in 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>2 years</time_frame>
    <description>Differences between groups are evaluated by change of total scores from the study intake to every 3 months in 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-mental State Examination (MMSE)</measure>
    <time_frame>2 years</time_frame>
    <description>Differences between groups are evaluated by change of total scores from the study intake to every 3 months in 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment Scale (MoCA)</measure>
    <time_frame>2 years</time_frame>
    <description>Differences between groups are evaluated by change of total scores from the study intake to every 3 months in 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time of relapse</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time of committing suicide</measure>
    <time_frame>2 years</time_frame>
    <description>It refers to the time of committing suicide and the time of success.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Laboratory examination</measure>
    <time_frame>2 years</time_frame>
    <description>Blood RT, Hepatic function and Renal function</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment Emergent Symptom Scale (TESS)</measure>
    <time_frame>2 years</time_frame>
    <description>TESS documents the presence of common side effects. Low scores or decrease in scores represent less side effects and high scores or increase in scores represent more side effects.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">4600</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Traditional Chinese Medicine</arm_group_label>
    <description>Including Zishui Qinggan Yin,Xiaoyao San, Longdan Xiegan Tang, Guipi Decoction, Ningshen Dingzhi Wan, HuangLian-EJiao decoction and Jiaotai Wan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCM plus antidepressants</arm_group_label>
    <description>This is a integrative therapy that refers to a new treating system including TCM and antidepressants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antidepressants</arm_group_label>
    <description>Antidepressants include Selective serotonin reuptake inhibitors (SSRIs), Norepinephrine-reuptake inhibitors and other antidepressants, such as Paroxetine, Citalopram, Venlafaxine, Sertraline, Trazodone, Maprotiline and so on.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Traditional Chinese Medicine</intervention_name>
    <description>Participants are treated with TCM twice per day according to syndrome differentiation. For example, the syndrome of one participant with depression is kidney deficiency. He will take Zishui Qinggan Yin twice per day before the breakfast and dinner.</description>
    <arm_group_label>Traditional Chinese Medicine</arm_group_label>
    <arm_group_label>TCM plus antidepressants</arm_group_label>
    <other_name>Chinese Medicine, Chinese Herb Medicine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidepressants</intervention_name>
    <description>Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.</description>
    <arm_group_label>TCM plus antidepressants</arm_group_label>
    <arm_group_label>Antidepressants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Depressive subjects with proven primary depression will be asked to participate in this
        study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects meeting all of the following criteria can be included in this study:

          -  Clinical diagnosis of depression

          -  The scores of Hamilton Depression scale ( HAMD )â‰¥18

          -  With stable vital signs, conscious mind and acceptable communication ability

          -  Can use the mobile phone to do self-evaluation

          -  Male or female patients between 18 and 65 years old

          -  Signing the informed consent and agreeing to participate in this study

        Exclusion Criteria:

        Subjects meeting anyone of the following criteria will be excluded from this study:

          -  Depression caused by other diseases

          -  Unstable vital signs

          -  Severe aphasia and agnosia causing disability to communicate

          -  Alcoholism and other substance dependence

          -  Diagnosis of other mental disorders except depression

          -  Serious hepatic or renal insufficiency

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qisheng Tang, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>The Third Affiliated Hospital of Beijing University of Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenjun Sun, MD, PHD</last_name>
    <phone>+86 18910259376</phone>
    <email>doctorsunwenjun@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miao Qu, MD, PHD</last_name>
    <email>qumiaotcm@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Beijing University of Chinese Medicine</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenjun Sun, MD, PHD</last_name>
      <phone>+86 18910259376</phone>
      <email>doctorsunwenjun@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Third Affiliated Hospital of Beijing University of Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Qisheng Tang</investigator_full_name>
    <investigator_title>MD, PHD</investigator_title>
  </responsible_party>
  <keyword>Telemedicine</keyword>
  <keyword>Chinese Medicine syndrome differentiation</keyword>
  <keyword>Long-term study</keyword>
  <keyword>Relapse rate</keyword>
  <keyword>Suicide rate</keyword>
  <keyword>Antidepressants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

